EUCTR2020-005289-32-DE进行中（未招募）1 期
An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
- •2. Participant has completed the originating inclacumab study within 30 days prior to the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related adverse event (AE), but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
- •3. Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1. Note: Female participants who become childbearing during the study must be willing to have a negative urine pregnancy test to remain in the study.
- •4. If sexually active, female participants of childbearing potential must use highly effective methods of contraception until 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
- •5. Participant has provided written informed consent/assent. For underage participants, both the consent of the participant’s legal representative or legal guardian and the participant’s assent (where applicable) must be obtained based on local requirement.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 482
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1. Female participant who is breastfeeding or pregnant.
- •2. Participant had an infusion-related reaction (IRR) in the originating inclacumab clinical study.
- •3. Participant withdrew consent from the originating inclacumab clinical study.
- •4. Participant was lost to follow-up from the originating inclacumab clinical study.
- •5. Participant has any other medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
研究者
相似试验
进行中（未招募）
1 期
A Study using Migalastat to see the safety and usefulness of the drug in patients with Fabry Disease.Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme a-galactosidase A.MedDRA version: 17.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004800-40-ATAmicus Therapeutics, Inc.100
进行中（未招募）
1 期
An extension to the phase 2 study A536-03 for the treatment of anemia in patients with myelodysplastic syndrome of low and intermediate risk groupsMyelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2014-001280-13-DEAcceleron Pharma Inc.153
尚未招募
3 期
A study to examine the long-term safety, tolerability, and effectiveness of Pozelimab and Cemdisiran combination therapy in adult patients with Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaJPRN-jRCT2031230013Aurand Lisa11
进行中（未招募）
1 期
An extension study to the A083-02 and A083-03 studies that evaluate the long-term effect of the ACE-083 investigational product in patients with Facioscapulohumeral Muscular Dystrophy (FSHD) previously participated in study A083-02 and also in patients with Charcot-Marie Tooth (CMT) disease type 1 and X who previously participated in study A083-03.Facioscapulohumeral Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10064087 Term: Facioscapulohumeral muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-000305-79-ESAcceleron Pharma Inc.150
进行中（未招募）
1 期
A Study using Migalastat to see the safety and usefulness of the drug in patients with Fabry Disease.EUCTR2011-004800-40-BEAmicus Therapeutics, Inc.100